Welcome to our dedicated page for Scisparc SEC filings (Ticker: SPRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading SciSparc’s latest clinical update can mean sorting through dozens of SEC exhibits, technical trial data, and shifting cash-runway notes. If you have ever wondered, “How do I track SciSparc insider trading Form 4 transactions before the market reacts?” you are not alone. Biotech filings are dense, and SciSparc’s dual focus on cannabinoid drug trials and hemp-product revenues makes them even more layered.
Stock Titan solves the problem. Our AI dissects every SciSparc quarterly earnings report 10-Q filing, highlights R&D spend, and links trial milestones so you can act quickly. Want the cash-burn figures without scrolling? Need SciSparc annual report 10-K simplified line-by-line? Prefer SciSparc Form 4 insider transactions real-time delivered the moment they hit EDGAR? It’s all here, alongside AI-powered summaries that turn medical jargon into plain language. We also cover every 8-K; search “SciSparc 8-K material events explained” and arrive straight at our tagged excerpts.
Whether you’re monitoring understanding SciSparc SEC documents with AI, comparing drug-development timelines, or checking a SciSparc proxy statement executive compensation, our platform offers:
- Real-time alerts for SciSparc executive stock transactions Form 4
- AI summaries that answer “SciSparc SEC filings explained simply” in seconds
- Complete coverage of S-1s, 10-Ks, 10-Qs, 8-Ks, and more—with direct links to exhibits
- Contextual metrics: dilution risk, patent counts, and trial phase progress
No more digging through 200-page PDFs. Stock Titan’s expert analysis and instant updates transform SciSparc earnings report filing analysis into actionable insight you can trust.
SciSparc Ltd. entered into an asset and share purchase agreement to obtain a controlling interest in Miza III Ventures Inc. by transferring its pharmaceutical portfolio and approximately 50.9% of SciSparc Nutraceuticals Inc.
At closing, SciSparc will receive 63,300,000 Miza common shares at CAD 0.25 per share, 4,000,000 five‑year warrants at an exercise price of CAD 0.25, and up to 48,000,000 contingent shares upon milestones. This represents a post‑closing equity interest of 75% in Miza, or up to approximately 84% if all milestones are achieved. The transaction reflects a value of approximately CAD 4.5 million for Miza and approximately CAD 15.8 million for the transferred assets.
Miza is expected to be renamed NeuroThera Labs Inc. and operate in pharmaceutical and supplemental sectors. Completion is anticipated by October 22, 2025, subject to conditions, with no assurance of closing. Upon closing and TSXV approval, SciSparc also plans an unsecured convertible note of up to CAD 1 million at 7%, maturing in two years and convertible at CAD 0.25 per share up to 4,000,000 shares. The securities will be issued under exemptions from U.S. registration.
SciSparc Ltd. disclosed a framework agreement to merge with AutoMax Ltd. The agreement is described as dated
SciSparc Ltd. announced that N2OFF shareholders approved a merger with MitoCareX, SciSparc's majority-owned subsidiary. The press release states the transaction was approved and identifies MitoCareX as a drug discovery company focused on therapies for resistant cancers, specifically naming pancreatic cancer and non-small cell lung cancer. The filing is presented as a current report (Form 6-K) and is signed by Oz Adler as Chief Executive Officer and Chief Financial Officer on September 30, 2025. The release does not include financial terms, an effective merger date, or post-transaction ownership percentages.
SciSparc Ltd. disclosed the launch of an innovative quantum computing-enabled 3D protein modeling initiative intended to support AI-driven drug discovery. The report cites the program name and presents a company signature by Oz Adler as Chief Executive Officer and Chief Financial Officer on
FAQ
What is the current stock price of Scisparc (SPRC)?
What is the market cap of Scisparc (SPRC)?
